Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Spero Therapeutics, Inc. (SPRO) is a Biotechnology company based in US with a market capitalization of $79.9M. Revenue grew 24.3% year-over-year and free cash flow was negative at -$12.6M. This page tracks SPRO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 32 employees · IPO Nov 2, 2017
Valuation
Valuation & price
$2.79as of May 17, 2026· -6.4% vs 52w high
19.2
P/E ratio
Latest-FY diluted EPS
1.35
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$79.9M
Market cap
24.3%
Revenue growth (YoY)
100.0%
Gross margin
-$12.6M
Free cash flow (USD)
-$37.4M
Net debt
Net cash position
3.7%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
1
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 13, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 14, 2026Filing
License Agreement Signed
- 8-K eventJun 25, 2026Filing
Stockholder Meeting Results
- 8-K eventJun 22, 2026Filing
FDA Approval
- 8-K eventMay 13, 2026Filing
Earnings Release
- Quarterly reportMay 13, 2026Filing
10-Q Filed
- Insider sellMay 6, 2026Filing
Insider Sell $63KRajavelu Esther · See Remarks · $63.4K
Questions
Frequently asked questions
What is Spero Therapeutics, Inc.'s market cap?
Spero Therapeutics, Inc. (SPRO) has a market capitalization of $79.9M.
What is SPRO's P/E ratio?
SPRO trades at a price-to-earnings ratio of 19.2, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
What is SPRO's price-to-book (P/B) ratio?
SPRO trades at 1.35 times book value per share.
Are insiders buying SPRO stock?
SEC Form 4 filings show no open-market insider buys at Spero Therapeutics, Inc. in the last 90 days (1 sell).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.